Literature DB >> 27879986

Anticholinergic Burden in Older Adults with Mild Cognitive Impairment.

Ariel R Green1, Esther Oh2,3,4, Liam Hilson5, Jing Tian6, Cynthia M Boyd1,7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27879986      PMCID: PMC5521962          DOI: 10.1111/jgs.14554

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


× No keyword cloud information.
  7 in total

1.  Forecasting the global burden of Alzheimer's disease.

Authors:  Ron Brookmeyer; Elizabeth Johnson; Kathryn Ziegler-Graham; H Michael Arrighi
Journal:  Alzheimers Dement       Date:  2007-07       Impact factor: 21.566

2.  Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.

Authors:  Shelly L Gray; Melissa L Anderson; Sascha Dublin; Joseph T Hanlon; Rebecca Hubbard; Rod Walker; Onchee Yu; Paul K Crane; Eric B Larson
Journal:  JAMA Intern Med       Date:  2015-03       Impact factor: 21.873

3.  The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers.

Authors:  John C Morris; Sandra Weintraub; Helena C Chui; Jeffrey Cummings; Charles Decarli; Steven Ferris; Norman L Foster; Douglas Galasko; Neill Graff-Radford; Elaine R Peskind; Duane Beekly; Erin M Ramos; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Oct-Dec       Impact factor: 2.703

Review 4.  Risk factors for the progression of mild cognitive impairment to dementia.

Authors:  Noll L Campbell; Fred Unverzagt; Michael A LaMantia; Babar A Khan; Malaz A Boustani
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

Review 5.  American Geriatrics Society identifies another five things that healthcare providers and patients should question.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2014-02-27       Impact factor: 5.562

Review 6.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.

Authors:  Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

Review 7.  The cognitive impact of anticholinergics: a clinical review.

Authors:  Noll Campbell; Malaz Boustani; Tony Limbil; Carol Ott; Chris Fox; Ian Maidment; Cathy C Schubert; Stephanie Munger; Donna Fick; David Miller; Rajesh Gulati
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

  7 in total
  5 in total

1.  Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden.

Authors:  Ariel R Green; Liza M Reifler; Cynthia M Boyd; Linda A Weffald; Elizabeth A Bayliss
Journal:  Drugs Aging       Date:  2018-03       Impact factor: 3.923

Review 2.  Anticholinergic burden for prediction of cognitive decline or neuropsychiatric symptoms in older adults with mild cognitive impairment or dementia.

Authors:  Martin Taylor-Rowan; Olga Kraia; Christina Kolliopoulou; Anna H Noel-Storr; Ahmed A Alharthi; Amanda J Cross; Carrie Stewart; Phyo K Myint; Jenny McCleery; Terry J Quinn
Journal:  Cochrane Database Syst Rev       Date:  2022-08-22

3.  Potential Targets for Deprescribing in Medically Complex Older Adults with Suspected Cognitive Impairment.

Authors:  Juliessa M Pavon; Theodore S Z Berkowitz; Valerie A Smith; Jaime M Hughes; Anna Hung; Susan N Hastings
Journal:  Geriatrics (Basel)       Date:  2022-05-19

4.  National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults.

Authors:  Taeho Greg Rhee; Yookyung Christy Choi; Gregory M Ouellet; Joseph S Ross
Journal:  J Am Geriatr Soc       Date:  2018-03-26       Impact factor: 5.562

Review 5.  Anticholinergic Drugs in Geriatric Psychopharmacology.

Authors:  Jorge López-Álvarez; Julia Sevilla-Llewellyn-Jones; Luis Agüera-Ortiz
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.